|Awarded On||August 18, 2021|
|Title||Development of TCR-based immunotherapies targeting hotspot EGFR mutations for the treatment of non-small cell lung cancer|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Alexandre Reuben|
|Cancer Sites||Head and Neck, Lung and Bronchus, Skin|
*Pending contract negotiation
Lung cancer has is responsive to immunotherapy due to the large number of mutations it harbors, which serve as foreign antigens detected by the immune system. However, a majority of patients still does not respond to these therapies. Tumor heterogeneity contributes to the lack of success of these therapies, by ensuring different cells within the same tumor present different antigens. This limits the ability of T cells to kill all tumor cells, rather confining them to the subset which express a specific antigen. One reason for this is the non-essential nature of the mutations from which these antigens are derived, which allows a tumor to lose these antigens as it evolves without serious conse...